BioSpace News Archive

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020.

Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it will be participating in the Piper Sandler 32nd Annual Virtual Healthcare Conference, scheduled to be held December 1 to 3, 2020.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported a positive two-year clinical outcome following the first Allocetra™ treatment of a hospitalized patient with erosive osteoarthritis, a rare bone disease, which has no approved nor effective treatment options and typically involves rapid destruction of hip and shoulder bones.

Canada’s response to the COVID-19 pandemic is guided by science, and one of the tools used to inform decisions is the Public Health Agency of Canada’s Global Public Health Intelligence Network, an early warning system for potential public health threats worldwide.

St. Jude Children’s Research Hospital® becomes the first AmazonSmile charity to reach the $10 million donation milestone through the program.

Narayana Health, headquartered in Bengaluru, India, has joined the TriNetX global health research network to help increase access to data that can drive innovation and expose them to more locally relevant global clinical trials.

- New investors include Viking Global Investors, General Atlantic, and Cormorant Asset Management, with an expanded position by Venrock Healthcare Capital Partners - Phase 2 study of PHVS416 expected to initiate in 2021

Endo International plc announced the expiration of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with the previously announced tender offer by Beta Acquisition Corp...

Partnership brings together leaders in their respective fields to advocate for an innovative, science-based approach to pandemic management

Clarametyx Biosciences Inc. (“Clarametyx”), a preclinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms, today announced that CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to accelerating antibacterial research and development,